Astrana Health (ASTH) Following Results The Bull Case Still Looks Undervalued

Astrana Health (ASTH) just posted third quarter and nine month results to September 30, 2026, reporting net income of US$12.95 million and US$47.13 million, respectively, along with higher reported earnings per share.

The earnings release has landed against a backdrop of strong share price momentum for Astrana Health, with a year-to-date share price return of 54.68% and a 90-day share price gain of 9.09%, despite a 1-day dip of 1.66% to US$39.01.

Scan how Astrana Health fits alongside other potential breakout opportunities with our hand-picked list of 21 high quality undiscovered gems in today's market.

Astrana Health now shows stronger earnings on paper alongside a sharp share price run. The real question is whether that improvement is already fully reflected in the current valuation.

Most Popular Narrative: 24% Undervalued

On the most followed view of Astrana Health, the narrative fair value of $51.67 sits well above the last close at $39.01. This puts the focus squarely on whether the concentrated full risk and AI driven model can justify that gap over time.

The main thing that has to go right is that Astrana Health continues to convert and manage more members in full-risk arrangements while its AI-enabled operating system keeps driving G&A efficiency, free cash flow generation, and successful integration of deals like Prospect despite ongoing Medicaid churn and cybersecurity scrutiny.

See why 6 investors see Astrana Health as 24% undervalued.

This widely tracked thesis uses a 7.54% discount rate and arrives at a fair value of $51.67, compared with Astrana Health's current market value of about $2.03b and share price of $39.01, which implies a 24.5% discount to that estimate.

The same framework assumes revenue growth of 8.96% and a profit margin of 2.94%, with the stock trading on a future P/E of 23.89x that is below the 24.3x level cited for the broader US Healthcare industry in the narrative. It is also described as being backed by analyst forecasts that earnings could compound meaningfully if the full risk membership mix, AI operating platform and cash flow deployment play out as expected.

On these narrative assumptions, the valuation hinges on whether you think Astrana Health can keep converting members into higher quality, full risk contracts and maintain free cash flow strength while managing reimbursement, acquisition and cybersecurity risks. Any shortfall there would make the implied future earnings and multiple harder to support.

Result: Fair Value of $51.67 (UNDERVALUED)

Still, the story can change quickly if reimbursement for Medicare and Medicaid tightens, or if the recent cybersecurity issues at a subsidiary escalate into larger legal or cost burdens.

Find out about the key risks to this Astrana Health narrative.

Next Steps

If this mix of optimism and concern around Astrana Health feels familiar, do not sit on the fence. Instead, weigh the competing signals for yourself by digging into the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Astrana Health?

Do not stop with Astrana Health alone. Broaden your watchlist with a few focused stock ideas that match different risk levels, income needs, and balance sheet preferences.

• Target potential mispricing by scanning a curated set of quality companies trading below their estimated value through the 42 high quality undervalued stocks.
• Lock in income-focused opportunities by reviewing the 6 dividend fortresses that offer higher yields and may help support a steadier return profile.
• Prioritize resilience by filtering for companies with strong finances using the list of solid balance sheet and fundamentals (24 results) that can better handle pressure when conditions change.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com